Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

G Caleb Alexander

Showing results (251-260 of 414) with videos related to

Pageof 42
Sort By:
JAMA|February 20, 2019
Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl ProductsJeffrey Eric Rollman, James Heyward, Lily Olson, et al.
Annals of the Rheumatic Diseases|November 2, 2019
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritisXintong Li, Kathleen M Andersen, Hsien-Yen Chang, et al.
Pharmacoepidemiology and Drug Safety|May 15, 2022
Use of prescription medications with cardiovascular adverse effects among older adults in the United StatesKatharine Ozenberger, G Caleb Alexander, Jung-Im Shin, et al.
JAMA Network Open|April 20, 2019
Association Between Pharmacy Closures and Adherence to Cardiovascular Medications Among Older US AdultsDima M Qato, G Caleb Alexander, Apurba Chakraborty, et al.
Journal of Clinical Epidemiology|April 10, 2021
More than two-dozen prescription drug-based risk scores are available for risk adjustment: A systematic reviewHemalkumar B Mehta, Lin Wang, Ioannis Malagaris, et al.
JAMA Internal Medicine|December 31, 2019
Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A ReviewJames Heyward, Lily Olson, Joshua M Sharfstein, et al.
Journal of the American Geriatrics Society|February 1, 2019
Differences in National Diabetes Treatment Patterns and Trends between Older and Younger AdultsScott J Pilla, Jodi B Segal, G Caleb Alexander, et al.
JAMA Internal Medicine|October 8, 2020
Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic ProductsThomas J Moore, Morgane C Mouslim, Jenna L Blunt, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|September 20, 2015
Effects of Televised Direct-to-Consumer Advertising for Varenicline on Prescription Dispensing in the United States, 2006-2009Yoonsang Kim, Rachel Kornfield, Yaru Shi, et al.
Psychiatric Services (Washington, D.C.)|January 3, 2013
Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophreniaStacie B Dusetzina, Benjamin L Cook, Alisa B Busch, et al.
Pageof 42

Showing results (251-260 of 414) with videos related to

Sort By:
Pageof 42
JAMA|February 20, 2019
Assessment of the FDA Risk Evaluation and Mitigation Strategy for Transmucosal Immediate-Release Fentanyl ProductsJeffrey Eric Rollman, James Heyward, Lily Olson, et al.
Annals of the Rheumatic Diseases|November 2, 2019
Comparative risk of serious infections among real-world users of biologics for psoriasis or psoriatic arthritisXintong Li, Kathleen M Andersen, Hsien-Yen Chang, et al.
Pharmacoepidemiology and Drug Safety|May 15, 2022
Use of prescription medications with cardiovascular adverse effects among older adults in the United StatesKatharine Ozenberger, G Caleb Alexander, Jung-Im Shin, et al.
JAMA Network Open|April 20, 2019
Association Between Pharmacy Closures and Adherence to Cardiovascular Medications Among Older US AdultsDima M Qato, G Caleb Alexander, Apurba Chakraborty, et al.
Journal of Clinical Epidemiology|April 10, 2021
More than two-dozen prescription drug-based risk scores are available for risk adjustment: A systematic reviewHemalkumar B Mehta, Lin Wang, Ioannis Malagaris, et al.
JAMA Internal Medicine|December 31, 2019
Evaluation of the Extended-Release/Long-Acting Opioid Prescribing Risk Evaluation and Mitigation Strategy Program by the US Food and Drug Administration: A ReviewJames Heyward, Lily Olson, Joshua M Sharfstein, et al.
Journal of the American Geriatrics Society|February 1, 2019
Differences in National Diabetes Treatment Patterns and Trends between Older and Younger AdultsScott J Pilla, Jodi B Segal, G Caleb Alexander, et al.
JAMA Internal Medicine|October 8, 2020
Assessment of Availability, Clinical Testing, and US Food and Drug Administration Review of Biosimilar Biologic ProductsThomas J Moore, Morgane C Mouslim, Jenna L Blunt, et al.
Nicotine & Tobacco Research : Official Journal of the Society for Research on Nicotine and Tobacco|September 20, 2015
Effects of Televised Direct-to-Consumer Advertising for Varenicline on Prescription Dispensing in the United States, 2006-2009Yoonsang Kim, Rachel Kornfield, Yaru Shi, et al.
Psychiatric Services (Washington, D.C.)|January 3, 2013
Racial-ethnic differences in incident olanzapine use after an FDA advisory for patients with schizophreniaStacie B Dusetzina, Benjamin L Cook, Alisa B Busch, et al.
Pageof 42